Neville J. Butcher

Neville J. Butcher

Auto-generated profile, based on publicly available information

Neville J. Butcher

University of Queensland

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2002 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
PDF file
NBN J Butcher
N J Butcher
SBS Boukouvala
S Boukouvala
ESE Sim
E Sim
RMRod Minchin
Rod Minchin

11 March 2014 in ACS Nano
Verified
Journal Article
Closed access
GMGysell M. Mortimer
Gysell M. Mortimer
NBNeville J. Butcher
Neville J. Butcher
AMAnthony W. Musumeci
Anthony W. Musumeci
ZDZhou J. Deng
Zhou J. Deng
DMDarren James Martin
Darren James Martin
RMRod Minchin
Rod Minchin

15 February 2016 in Nature Nanotechnology
Verified
Journal Article
Closed access
NBNeville J. Butcher
Neville J. Butcher
GMGysell M. Mortimer
Gysell M. Mortimer
RMRod Minchin
Rod Minchin

1 January 2012 in Pharmacological Reviews
Verified
Journal Article
Closed access
PDF file
NBNeville J. Butcher
Neville J. Butcher
RMRod Minchin
Rod Minchin
The human arylamine N-acetyltransferases first attracted attention because of their role in drug metabolism. However, much of the current literature has focused on their role in the activation and detoxification of environmental carcinogens and how genetic polymorphisms in the genes create predispositions to increased or decreased cancer risk. There are two closely related genes on chromosome 8 that encode the two human arylamine N-acetyltransferases—NAT1 and NAT2. Although NAT2 has restricted tissue expression, NAT1 is found in almost all tissues of the body. There are several single-nucleotide polymorphisms in the protein coding and 3′-untranslated regions of the gene that affect enzyme activity. However, NAT1 is also regulated by post-translational and environmental factors, which may be of greater importance than genotype in determining tissue NAT1 activities. Recent studies have suggested a novel role for this enzyme in cancer cell growth. NAT1 is up-regulated in several cancer types, and overexpression can lead to increased survival and resistance to chemotherapy. Although a link to folate homeostasis has been suggested, many of the effects attributed to NAT1 and cancer cell growth remain to be explained. Nevertheless, the enzyme has emerged as a viable candidate for drug development, which should lead to small molecule inhibitors for preclinical and clinical evaluation.

1 May 2004 in Journal of Biological Chemistry
Verified
Journal Article
Open access
NBNeville J. Butcher
Neville J. Butcher
AAAjanthy Arulpragasam
Ajanthy Arulpragasam
RMRod Minchin
Rod Minchin
Many drugs and chemicals found in the environment are either detoxified by N-acetyltransferase 1 (NAT1, EC 2.3.1.5) and eliminated from the body or bioactivated to metabolites that have the potential to cause toxicity and/or cancer. NAT1 activity in the body is regulated by genetic polymorphisms as well as environmental factors such as substrate-dependent down-regulation and oxidative stress. Here we report the molecular mechanism for the low protein expression from mutant NAT1 alleles that gives rise to the slow acetylator phenotype and show that a similar process accounts for enzyme down-regulation by NAT1 substrates. NAT1 allozymes NAT1 14, NAT1 15, NAT1 17, and NAT1 22 are devoid of enzyme activity and have short intracellular half-lives ( approximately 4 h) compared with wild-type NAT1 4 and the active allozyme NAT1 24. The inactive allozymes are unable to be acetylated by cofactor, resulting in ubiquitination and rapid degradation by the 26 S proteasome. This was confirmed by site-directed mutagenesis of the active site cysteine 68. The NAT1 substrate p-aminobenzoic acid induced ubiquitination of the usually stable NAT1 4, leading to its rapid degradation. From this study, we conclude that NAT1 exists in the cell in either a stable acetylated state or an unstable non-acetylated state and that mutations in the NAT1 gene that prevent protein acetylation produce a slow acetylator phenotype.

1 February 1998 in Pharmacogenetics
Verified
Journal Article
Closed access
NBNeville J. Butcher
Neville J. Butcher
KIKenneth E. Ilett
Kenneth E. Ilett
RMRod Minchin
Rod Minchin
Human JV-acetyltransferase type 1 (NAT1) catalyses the JV- or O-acetylation of various arylamine and heterocyclic amine substrates and is able to bioactivate several known carcinogens. Despite wide inter-individual variability in activity, historically, NAT1 was considered to be monomorphic in nature. However, recent reports of allelic variation at the NAT1 locus suggest that it may be a polymorphically expressed enzyme. In the present study, peripheral blood mononuclear cell NAT1 activity in 85 individuals was found to be bimodally distributed with approximately 8% of the population being slow acetylators. Subsequent sequencing of the individuals having slow acetylator status showed all to have either a C190T or GS60A base substitution located in the protein encoding region of the NAT1 gene. The C190T base substitution changed a highly conserved Arg64, which others have shown to be essential for fully functional NAT1 protein. The C190T mutation has not been reported previously and we have named it NAT1*17. The G560A mutation is associated with the base substitutions previously observed in the NAT1*1O allele and this variant (NAT1*14) encodes for a protein with reduced acetylation capacity. A novel method using linear PCR and dideoxy terminators was developed for the detection of NAT1*14 and NAT1*17. Neither of these variants was found in the rapid acetylator population. We conclude that both the C190T (NAT1*17) and G560A (NAT1*14) NAT1 structural variants are involved in a distinct NAT1 polymorphism. Because NAT1 can bioactivate several carcinogens, this polymorphism may have implications for Cancer risk in individual Subjects.